Efficacy of a glucose meter connected to a mobile app on glycemic control and adherence to self-care tasks in patients with T1DM and LADA: a parallel-group, open-label, clinical treatment trial
AUTOR(ES)
Oliveira, Felipe Martins de; Calliari, Luís Eduardo Procópio; Feder, Cecília Kauffman Rutenberg; Almeida, Maria Fernanda Ozorio de; Pereira, Mariana Vilela; Alves, Maria Thereza Teixeira de Almeida Fagundes; Garcia, Sônia Aparecida Dias; Reis, Ligia Dinara Donizeti; Salles, João Eduardo Nunes
FONTE
Arch. Endocrinol. Metab.
DATA DE PUBLICAÇÃO
2021-04
RESUMO
ABSTRACT Objective: The main aim of the study was to evaluate the patients’ glycemic control and adherence to self-care tasks. Materials and methods: Patients with type 1 diabetes mellitus (T1DM) or latent autoimmune diabetes of the adult (LADA) using a multiple daily injection (MDI) regimen with carbohydrate counting (n = 25, Subgroup B) or fixed insulin dose (n = 25, Subgroup C) were allocated to use the application (app) for 12 weeks. Both subgroups were compared with each other and against a control group (n = 25, Group A) comprising patients with T1DM or LADA treated with continuous subcutaneous insulin infusion (CSII) in a parallel-group, open-label, clinical treatment trial. All patients had glycated hemoglobin (A1C) levels measured and were asked to fill out the Diabetes Self-Management Profile (DSMP) questionnaire at study start and end. The patients were instructed to measure capillary glucose six times daily in study weeks 4, 8, and 12. Results: Mean A1C levels decreased 0.725% in Subgroup C in intragroup analysis (p = 0.0063), and had a mean variation of 0.834% compared with Group A (p = 0.003). Mean DSMP scores increased 5.77 points in Subgroup B in intragroup analysis (p = 0.0004) and increased by a mean of 6.815 points in relation to Group A (p = 0.002). Conclusion: OneTouch Reveal improved both A1C levels and DSMP scores in patients with T1DM or LADA compared with standard treatment (CSII).
Documentos Relacionados
- Efficacy and safety of amphotericin B deoxycholate versus N-methylglucamine antimoniate in pediatric visceral leishmaniasis: an open-label, randomized, and controlled pilot trial in Brazil
- Open-label, clinical phase I studies of tasquinimod in patients with castration-resistant prostate cancer
- Open-Label, Dose Escalation Study of the Safety and Pharmacokinetic Profile of Tefibazumab in Healthy Volunteers
- Occupational therapy in spinocerebellar ataxia type 3: an open-label trial
- Occupational therapy in spinocerebellar ataxia type 3: an open-label trial